Relative stability of meningococcal serogroup A and X polysaccharides |
| |
| Authors: | F. Berti M.R. Romano F. Micoli V. Pinto E. Cappelletti M. Gavini D. Proietti G. Pluschke C.A. MacLennan P. Costantino |
| |
| Affiliation: | 1. Novartis Vaccines, Via Fiorentina 1, I-53100 Siena, Italy;2. Novartis Vaccines Institute for Global Health, Via Fiorentina 1, I-53100 Siena, Italy;3. Swiss Tropical and Public Health Institute, Basel, Switzerland;4. MRC Centre for Immune Regulation, School of Immunity and Infection, College of Medicine and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK |
| |
| Abstract: | Prior to the introduction of the MenAfriVac™ serogroup A glycoconjugate vaccine in September 2010, serogroup A was the major epidemic disease-causing meningococcal serogroup in the African meningitis belt. However, recently serogroup X meningococcal (MenX) disease has received increased attention because of outbreaks recorded in this region, with increased endemic levels of MenX disease over the past 2 years. Whereas polysaccharide–protein conjugate vaccines against meningococcal serogroups A, C, W and Y (MenA, MenC, MenW, MenY) are on the market, a vaccine able to protect against MenX has never been achieved. |
| |
| Keywords: | Meningococcal vaccines Serogroup A Serogroup X Stability Neisseria meningitidis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
